大成生化科技(00809.HK)附属长春大合暂停生产至明年2月
大成生化科技(00809.HK)公布,由於非洲猪瘟的影响、中国与美国的贸易纠纷,以及长春大合的生产设施需要定期维修,集团藉此机会自今年8月起透过暂停生产设施的生产营运以提升定期维修的时间表。
长春大合为集团的间接全资附属,主要从事赖氨酸及蛋白赖氨酸等玉米生化产品的生产及销售。集团指,尽管生产设施的机器大修已於今年11月底完成,惟集团管理层经计及最新市况及集团的财务状况後,决定继续暂停生产设施的生产营运至农历新年後,暂拟直至明年2月中旬前後。考虑到长春大合的存货水平及将近农历新年前後期间行业淡季需求较低,集团预期长春大合将於恢复生产设施的生产营运前仍能继续其销售营运。
集团指,将密切观察市况,并会就恢复生产设施的生产营运进行可行性分析。根据集团的未经审核财务资料,今年首九个月,长春大合的收益及亏损净值分别占集团总收益及亏损净值的25.3%及37.4%。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.